Latest Conference Articles

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall, BS, MS, pointed out that an epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Denise Freitas, MD, reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.

Roger A. Goldberg, MD, MBA, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

Felipe Medeiros, MD, in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.

Shady Awwad, MD, in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

tPA treatment could provide benefits for patients with central retinal artery occlusion.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.

Ash Abbey, MD, discusses the COED trial, testing the efficacy of combining steroid and anti-VEGF therapy in patients with diabetic macular edema.

Results from our recent poll regarding AAO 2021 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in-person.

At ASRS, David Brown, MD, reported positive results at the head-to-head endpoints of KESTREL and KITE, but with continuing concerns about inflammation.

Nathan Steinle, MD, discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.

Carl Regillo, MD, takes us through the history of the port delivery system, from ideation to FDA approval.

The Academy's annual meeting is set for November 12 to 15 in New Orleans.

Dr. Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular edema (DME) patients.

A poll for retina specialists regarding their attendance at the 2021 American Academy of Ophthalmology Meeting in New Orleans, Louisiana. This poll is now closed.

In his presentation at ASRS 2021, Dr. Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular edema in patients with retinal vein occlusion.

Leo Kim, MD, PhD, discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

W. Lloyd Clark, MD, discusses his presentation at ASRS 2021, "Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR)."

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration.